Long-acting injectable HIV treatment is feasible, even during COVID-19
Lower CD4 count and unsuppressed HIV raise the risk for severe COVID-19
Homeless people with HIV prefer flexibility, in-person care and incentives
Few HIV infections among PrEP users in Brazil and Mexico, but challenges in Peru
Large UK study identifies increased cardiovascular risk in people living with HIV, including younger people
Twice-a-year injected drug shows promise for first-line HIV treatment
Adolescent-centred interventions lead to a 30-percentage-point increase in viral suppression in Namibia, and a 20-percentage-point increase in Nigeria
Healthcare workers in Cape Town ambivalent about patients who disengage from HIV treatment
People with HIV should be prioritised for COVID-19 vaccination due to higher risk, WHO recommends
Sexual violence against women and girls in Uganda increased during the COVID-19 pandemic
Hepatitis C virtually eliminated in people with HIV in the Netherlands
Most countries with the greatest burden of HIV still don’t recommend dolutegravir for all
Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing therapy
